Streetbeat News

Price Targets

ARHS

Craig-Hallum analyst Jeremy Hamblin maintains a Buy rating on Arhaus (NASDAQ:ARHS) and raises the price target from $15 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:46 pm

ACET

BTIG analyst Justin Zelin maintains a Buy rating on Adicet Bio (NASDAQ:ACET) but has lowered the price target from $20 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:44 pm

BLFS

Craig-Hallum analyst Matt Hewitt maintains a 'Buy' rating on BioLife Solns (NASDAQ:BLFS), but has lowered the price target from $29 to $23.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:43 pm

BNGO

BTIG analyst Mark Massaro maintains a Buy rating on Bionano Genomics (NASDAQ:BNGO) and raises the price target from $2 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:42 pm

ANIP

Guggenheim analyst Vamil Divan maintains a Buy rating on ANI Pharmaceuticals (NASDAQ:ANIP) and raises the price target from $62 to $72.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:38 pm

FTCI

Piper Sandler analyst Kashy Harrison maintains a Neutral rating on FTC Solar (NASDAQ:FTCI) and lowers the price target from $3 to $2.5.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:37 pm

IPSC

Piper Sandler analyst Edward Tenthoff maintains an Overweight rating on Century Therapeutics (NASDAQ:IPSC) but lowers the price target from $14 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:36 pm

RPAY

Repay Holdings reported better-than-expected Q2 revenue results, leading to a rise in its share prices. Morgan Stanley and Credit Suisse have also raised their price targets on the stock.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:36 pm

ARHS

Guggenheim analyst Steven Forbes maintains a Buy rating on Arhaus (NASDAQ:ARHS) and raises the price target from $12 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:34 pm

GDRX

Guggenheim analyst Sandy Draper maintains a Buy rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $8 to $10.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 7:33 pm